Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

AstraZeneca Add to portfolio

NYA:AZN, Feb 21, 09:04 UTC

Latest NYA:AZN News

Filter your feed

Apply Filter

Wednesday, February 19


News

DIRECTOR DEALINGS: AstraZeneca Non-Executive...

AZN AZN

(Alliance News) - AstraZeneca PLC said Wednesday that Non-Executive Director Michel Demare on ... (Alliance News) - AstraZeneca PLC said Wednesday that Non-Executive Director Michel Demare on Monday purchased around GBP51,000 in stock. Demare bought 700 shares at a price of GBP73.13 per share, though AstraZeneca did not disclose how many shares he now holds overall. Shares in the FTSE 100-listed pharmaceutical giant were up 1.4% at 7,625.00 pence on Wednesday afternoon in London. Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

Here’s why Astrazeneca is one of the most expensive shares on the market

AZN AZN

Here’s why Astrazeneca is one of the most expensive shares on the market. It has long been understood that cheap stocks have a tendency to outperform expensive stocks in the stock market. While this is not true every single year, over almost every 3-year cycle in the stock market, cheap (or value) stocks outperform. This phenomenon has created the cult of 'Value Investing' born of the writings of Benjamin Graham and the amazing success of its arch proponent Warren Buffett. In the 4th edition of his groundbreaking investment research tome What Works on Wall St, O’Shaughnessy shows that composite value factors based on a mix of metrics dramatically beat the market over a multi-decade period.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, February 16


News

Why I’d avoid AstraZeneca shares and buy this FTSE 100 stock

AZN AZN

The AstraZeneca (LSE: AZN) share price has risen by more than 90% since May 2016 as investors have bought into CEO Pascal Soriot’s more focused strategy for the business. However, the shares dipped on Friday after Mr Soriot warned that 2020 earnings may be hit by the coronavirus outbreak. Core earnings of $3.50 per share were only slightly below broker forecasts of $3.59 per share. Although most companies use adjusted profits, I feel that AstraZeneca’s approach to calculating its core profits is aggressive and excludes some costs that should really be left in. The group’s core operating profit was $6,436m. But its reported operating profit, which includes all standard accounting costs, fell by 14% to $2,924m. This non-cash accounting charge relates to the gradual reduction in value of intellectual property such as patents, licences and software. As you can imagine, this kind of asset is a big part of a pharmaceutical business — AstraZeneca carries about $21bn of intangible assets on its balance sheet, reflecting historic spending.

Read Full Details

Topics:
  • Business
  • Financial

Saturday, February 15


News

AstraZeneca Announces Q4 Financial Results, Coronavirus Fears Weigh on Guidance

AZN AZN

Feb 14, 2020 8:14PM EST. AstraZeneca Announces Q4 Financial Results, Coronavirus Fears Weigh on Guidance | NASDAQ. AstraZeneca (NYSE: AZN) announced its fourth-quarter and 2019 full-year financial results on Friday morning. While the company reported impressive sales growth in a number of its top-selling drugs, investors are worried that the novel coronavirus outbreak could significantly eat away at the company's 2020 sales. Product sales accounted for the majority of this figure, around $6.25 billion, which is up a healthy 8.4% from Q4 2018. Another top performer for the company, a cancer drug called Imfinzi, is up 62% from Q4 2018 and brought in $424 million. The company's 2020 guidance expects high-single-digit to low-double-digit percentage increases in revenue assuming that the coronavirus doesn't last more than a few months.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial

Friday, February 14


News

Astrazeneca warns on 'unfavourable impact' from coronavirus outbreak

AZN AZN

Pharmaceutical giant AstraZeneca has warned that the impact from the coronavirus outbreak will hit the business for "up to a few months", making projections for the year ahead tricky, the company said. Bosses said the virus, called Covid-19, could particularly hit their business over rivals because China, which first reported the outbreak, is the firm's fastest-growing market. The warning came following a 15% rise in sales during the year to 23.5 billion dollars (£18 billion) - including a 35% sales boost in China alone. However, sales slowed in the final quarter of the year, rising just 9% compared with an 18% rise in the third quarter. Bosses at the Cambridge-based business added that sales in its three therapy areas of oncology, cardiovascular, renal and metabolism (CVRM) and respiratory grew during the year by 44%, 9% and 10% respectively.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

AZN AZN

ZacksFebruary 14, 2020, 2:21 PM UTC. AstraZeneca AZN reported dismal fourth-quarter results with earnings and sales both missing the Zacks Consensus Estimate. Fourth-quarter 2019 core earnings of 45 cents per American depositary share missed the Zacks Consensus Estimate of 53 cents. Among the newer medicines, Lynparza sales rose 69% year over year and 7.3% sequentially to $351 million in the quarter on the back of expanded use in ovarian and breast cancer, as well as solid growth in emerging markets. AstraZeneca markets Lynparza in partnership with Merck MRK. Sales of other legacy drugs including Zoladex, Arimidex, Atacand and Daliresp/Daxas grew in the quarter while sales of others like Faslodex, Casodex, and Synagis declined.

Read Full Details

Topics:
  • Business
  • Financial
News

AstraZeneca's CEO reaffirms 2021 targets

AZN AZN

LONDON (Reuters) - AstraZeneca <AZN.L> is fully on track to reach its earnings goal for next year, its chief executive told Reuters on Friday after the British drugmaker's quarterly earnings missed market expectations. "What we've said is that by 2021 we would cover the dividend in full and we would target an operating margin north of 30%. This is very much in line with what we are targeting," CEO Pascal Soriot said, following the release of fourth-quarter results. AstraZeneca is moving into a third year of sales growth after changes driven by Soriot and now has nine drugs with annual sales of more than $1 billion but analysts and investors have been looking for clues whether the company's earnings growth would keep up. The company's 2019 operating margin, or earnings before interest and tax over total revenue, was 26%. AstraZeneca's CEO reaffirms 2021 targets.

Read Full Details

Topics:
  • Business
  • Financial
News

What to Watch: AstraZeneca warns on coronavirus, RBS rebrand and markets' stimulus hopes

AZN AZN +2 more AZN AZN RBS FB

Here are the top business, market and economic stories you should be watching today in the UK, Europe, and abroad:. AstraZeneca warns on coronavirus. The UK drugmaker AstraZeneca (AZN.L) has warned it expects the coronavirus to hits its growth targets. Analysts had warned anything below double-digit sales growth marked a disappointment, according to Reuters. But Russ Mould, investment director at AJ Bell, said the 2019 results were “fairly decent.” He added that the company was focusing on developing treatments that were harder for rivals to replicate, after “suffering from over-reliance on blockbuster drugs” that later lost patent protection in the past. Royal Bank of Scotland (RBS.L) nearly doubled annual profits for the second year in a row on Friday, as new chief executive Alison Rose announced a sweeping new strategy and plans to rename the bank.

Read Full Details

Topics:
  • Business
  • Financial
News

AstraZeneca warns on ‘unfavourable impact’ from coronavirus outbreak

AZN AZN

Pharmaceutical giant AstraZeneca has warned that the impact from the coronavirus outbreak will hit the business for “up to a few months”, making projections for the year ahead tricky, the company said. Bosses said the virus, called Covid-19, could particularly hit their business over rivals because China, which first reported the outbreak, is the firm’s fastest-growing market. Revenues are expected to grow by high single digits or low double digits, but these could change, AstraZeneca said. The warning came following a 15% rise in sales during the year to 23.5 billion dollars (£18 billion) – including a 35% sales boost in China alone. However, sales slowed in the final quarter of the year, rising just 9% compared with an 18% rise in the third quarter.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Stocks - Europe Heads Lower; RBS, Renault, AstraZeneca Weigh

AZN AZN +2 more AZN AZN RBS RNO

Investing.com - European stock markets pushed lower Friday, with early gains overturned by losses in index heavyweights RBS (LON:RBS), Renault (PA:RENA) and AstraZeneca (LON:AZN). At 03:50 ET (0840 GMT), the U.K.'s FTSE index was trading 16 points, or 0.2%, lower, France's CAC 40 was down 11 points, also a 0.2% drop, while the DAX was largely flat. Shares in British banking group RBS (LON:RBS) slumped 5% despite reporting earnings significantly above expectations early Friday, prompting it to announce a special dividend after group net profit soared to 4.2 billion pounds. This follows Nissan, in which Renault is a major shareholder, cutting its annual profit forecast and canceling its dividend for the second half of the year. AstraZeneca shares (LON:AZN) dropped 1.5% after its core operating profit fell in the final quarter of the year, missing expectations.

Read Full Details

Topics:
  • Business
  • Financial